MADISON, Wis.–Promega Corporation announces the launch of a breakthrough cell-based biosensor technology, termed GloSensor™ Technology. The non-lytic, live-cell GloSensor cAMP Assay is the first application of the patent-pending technology, which features a genetically engineered form of firefly luciferase. The benefit to screeners and scientists alike will be more biologically relevant data captured directly from living cells.

cAMP is a key signaling molecule for many G-protein coupled receptors. GloSensor cAMP Assay is the first bioluminescent cell-based biosensor for the direct, intracellular kinetic monitoring of cAMP, and ideally suited to HTS and uHTS applications. “Early testers of the assay are telling us the ease and performance of the assay are phenomenal,” says Neal Cosby, Promega Drug Screening Manager. “The kinetic profiling of cAMP afforded by this new technology will give scientists better insight into the biology of living cells under various treatments, such as agonist and antagonist screening.” Because researchers simply combine cells, compounds and GloSensor cAMP Assay Reagent, the technology offers ‘zero-step’ assay potential.

Collaborator and company-sponsored presentations will be given at SBS 14th Annual Conference & Exhibition (April 6-10, 2008) in St Louis. Promega scientists who developed the genetically engineered bioluminescent biosensors will be present at SBS to discuss the new technology with interested parties.

About Promega

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 14 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.